Novavax Shares Fall After Respiratory Virus Vaccine Has Unfavorable Clinical Trial Results
Meanwhile, Peloton Therapeutics raised $52.4 million in venture capitol to support clinical trials for a new kidney cancer treatment.
The Wall Street Journal:
Novavax Shares Plummet After Unfavorable Results Of Trials
Novavax Inc. shares fell 84% in after-hours trading Thursday after the vaccine company reported unfavorable results from two clinical trials. A drug candidate known as the RSV F Vaccine didn’t meet its efficacy goals, including the primary objective related to prevention of respiratory tract disease. (Beckerman, 9/15)
Dallas Morning News:
Dallas-Based Renal Cancer Therapy Developer Raises $52.4 Million
Peloton Therapeutics, Inc. has raised $52.4 million in venture capital, which it plans to use to support clinical trials on a novel kidney cancer treatment it has developed. The Dallas-based biotechnology company completed a Series D financing round, and added new investor Foresite Capital Management, a private equity and venture capital firm from San Francisco that focus on emerging healthcare drug and device opportunities. (Rice, 9/15)
